Trials / Completed
CompletedNCT04266028
Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
A Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety and Tolerability of Subcutaneous Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Desentum Oy · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Randomized, double-blind placebo-controlled phase I study to investigate the safety and tolerability of ascending doses of DM-101 in adult subjects with birch pollen allergy.
Detailed description
The study will be carried out in a single study site located in Finland.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | DM-101 | DM-101 administered by subcutaneous (SC) injection |
| BIOLOGICAL | Placebo to match DM-101 | Placebo to match DM-101 administered by SC injection |
Timeline
- Start date
- 2020-02-11
- Primary completion
- 2021-05-31
- Completion
- 2021-05-31
- First posted
- 2020-02-12
- Last updated
- 2023-03-21
- Results posted
- 2023-03-21
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT04266028. Inclusion in this directory is not an endorsement.